Pharma IP Alert: Recent P-IV Filings for Spinraza & Austedo XR + Delhi HC’s ₹152 Cr Damages Precedent
Introduction
The pharmaceutical landscape is rapidly evolving with strategic P-IV challenges and complex generic developments. Our latest newsletter explores critical updates from the FDA website (as of April 13, 2026) and a significant Delhi High Court judgment that could set a precedent for future pharmaceutical infringement damages in India.
Recent Paragraph IV (P-IV) Filings: Strategic Market Entries
Generic manufacturers are increasingly targeting high-value orphan drugs and complex formulations to bypass long-term patent barriers.
1. Nusinersen (Spinraza) - Complex Generic Challenge
- Drug Profile: An antisense oligonucleotide (ASO) for Spinal Muscular Atrophy (SMA).
- The Opportunity: While 2023 US sales were approximately $500 million, the innovator recently secured a new high-dose regimen approval on March 30, 2026, to shift the patient base before the 12 mg version goes generic.
- Key Players: Industry analysis suggests potential involvement from Indian firms like Natco and Cipla.
2. Deutetrabenazine (Austedo XR) - Strategic Life Cycle Management
- The Challenge: A P-IV filing has been made for 6 mg, 12 mg, and 24 mg strengths, directly challenging Teva’s LCM plan.
- Projected Market: Combined US sales for Austedo were projected to reach $1.5–$1.7 billion by late 2025.
- Timeline: The applicant seeks to enter the market as early as 2031, circumventing a patent that extends to 2041.
3. Upadacitinib (Rinvoq LQ) - Pediatric Orphan Formulations
- Target: A 1 mg/mL oral solution designed for patients who cannot swallow tablets.
- Regulatory Status: Filed within two years of the April 2024 approval.
- Barrier: Orphan Drug Exclusivity remains in place until April 2031.
4. Risdiplam (Evrysdi) - High-Stakes SMA Segment
- Focus: A P-IV challenge in March 2026 targeting the newly approved 5 mg tablet version.
- Legal Context: Natco recently cleared legal hurdles in India, with the Supreme Court of India allowing its generic launch as of October 2025.
Pharmaceutical Manufacturing & R&D News
- Novo Nordisk Breakthrough: A late-stage trial for an oral GLP-1 drug successfully lowered blood sugar in children (aged 10–17) with Type 2 diabetes.
- Data Innovation: CMAC in the UK has successfully connected siloed data systems to provide real-time answers for pharmaceutical manufacturing, potentially accelerating drug development.
Landmark IP Ruling: CCAI vs. Rosenberger (Delhi High Court)
While this case involves telecommunications technology, the March 30, 2026, judgment is crucial for the pharmaceutical industry regarding how Indian courts calculate patent infringement damages.
- The Precedent: The court awarded ₹152.32 Crores ($1.6 billion equivalent) in damages, utilising a 20% royalty rate on sales.
- Industry Impact: This underscores the financial risk foreign firms and local manufacturers face if they fail to circumvent or license valid patents in the Indian market
#ParagraphIV
#PharmaIP
#Spinraza
#Rinvoq
Contents
Recent P-IV filings
General information
Novo Nordisk's diabetes pill cuts blood sugar in key trial in children
Manufacturing data innovation set to accelerate medicine development
Intellectual Property
Communication Components Antenna Inc Vs Rosenberger Hochfrequenztechnik GmbH: Delhi HC
Recent P-IV filings
We follow P-IV filings on the FDA website. The recent update was on 13 April 2026.
General information
Novo Nordisk's diabetes pill cuts blood sugar in key trial in children
Novo Nordisk's (NOVOb.CO), opens new tab oral GLP-1 drug significantly lowered blood sugar levels in children and adolescents with type 2 diabetes, meeting the main goal of a late stage trial, the drugmaker said on Thursday.
The Danish drugmaker tested the pill in 132 patients aged 10 to 17 over a 26 week period.
News here
Manufacturing data innovation set to accelerate medicine development
CMAC, an academic research centre for pharmaceutical manufacturing and digital CMC in the UK, led by the University of Strathclyde, has connected data across multiple, siloed systems for the first time.
It accelerates the development of new medicines and processes by enabling participating research teams and leading pharmaceutical companies to access real-time answers to questions about their entire data estate, replacing previously manual processes.
News here
Intellectual Property
Communication Components Antenna Inc Vs Rosenberger Hochfrequenztechnik GmbH: Delhi HC
This is a summary of the judgment in Communication Components Antenna Inc (CCAI). vs. Rosenberger Hochfrequenztechnik Gmbh & Co. KG (RHGC). pronounced by the High Court of Delhi on March 30, 2026.
This is not a pharmaceutical or chemical-related case, but it is important to note that a foreign firm could seek substantial damages in an infringement case. This could set a precedent for subsequent pharmaceutical infringement cases in India.
Since I don’t understand the science related to telecommunications, most of the paragraphs are copied directly from the decision. There may be errors in the facts of the technology, but what is more important is understanding how the court arrived at the damage calculations.
Background and Parties
The Plaintiff, Communication Components Antenna Inc. (CCAI), is a Canadian company specialising in cellular base station products. The Defendants include Rosenberger Hochfrequenztechnik GmbH, a German antenna manufacturer, and its various Indian and Chinese subsidiaries (collectively the "Rosenberger Group"). CCAI filed the suit seeking a permanent injunction against the Defendants for infringing its Indian Patent No. 240893 (IN’893), titled "Asymmetrical Beams For Spectrum Efficiency".
The Suit Patent (IN’893)
Granted in June 2010 with a priority date of March 17, 2006, the patent relates to split-sector antennas that use asymmetrical beam patterns to increase subscriber capacity in cellular networks. Conventionally, symmetrical beams were used, but increasing the number of sectors led to excessive handover zones, causing interference and call drops. IN’893 solves this by replacing a symmetrical sector antenna with a split-sector antenna emitting asymmetrical beams. This maintains the original critical coverage area while significantly reducing handover zones and doubling subscriber capacity.
Invalidity Challenges
The Defendants challenged the patent's validity on several grounds under Section 64 of the Patents Act, 1970.
Novelty and Inventive Step: Defendants relied on several prior arts, including "Gabriel" (US2005/0030249) and a "TenXc Article". The Court rejected these, noting that Gabriel addressed incidental asymmetry in a single-beam system and did not contemplate higher-order sectorization or maintaining the critical coverage area. Regarding inventive step, the Court criticised the Defendants' Dartboard Model approach—slinging unrelated prior arts at the patent in hopes of hitting the mark—without showing how a person skilled in the art would link them. The Court held that the jump from existing technology to IN’893 was not obvious.
Insufficiency of Disclosure: Defendants argued that terms like "critical coverage area" and "induced asymmetry" were not defined. The Court found that these terms, while perhaps unique to the patent, were easily understood by experts in the telecommunications industry. It further ruled that the provided power and phase weightings were illustrative embodiments sufficient for a person skilled in the art to work the invention.
Infringement Analysis
CCAI identified 11 infringing Rosenberger antenna models. CCAI’s expert used MATLAB to simulate beam patterns from the patent’s disclosed weightings and overlaid them with the beam patterns from Rosenberger’s product brochures. The expert concluded the patterns were nearly identical in shape, asymmetry, and performance characteristics.
The Court noted Rosenberger’s "suspect" conduct in pulling down brochures during the suit and failing to produce their actual antenna beam patterns. Furthermore, a Rosenberger internal brochure (Exh. PW-2/10) compared their beams to CCAI’s, proving they were pitching identical technology to customers like Reliance Jio. The Court found the Plaintiff had discharged its onus and declared the Defendants were infringing IN’893.
Damages and Relief
CCAI sought damages based on loss of profits and price erosion. Evidence showed that Rosenberger’s lower quotes forced CCAI to reduce prices, and Rosenberger sold over 1.27 lakh antennas compared to CCAI’s 30,000.
The Court awarded:
Permanent Injunction: Restraining the Defendants from manufacturing or selling the infringing antennas until the patent’s expiry in March 2027.
Damages: The Court had previously directed a deposit of 25% of the claimed damages (amounting to ₹290 Crores), given the Defendants' lack of Indian assets and depreciating financial position.
The final damage amount the Defendants are liable to pay to the Plaintiff is ₹152,32,36,783.90 (Rupees One Hundred and Fifty-Two Crores Thirty-Two Lakhs Thirty-Six Thousand Seven Hundred Eighty-Three and Ninety Paise).
Breakdown of the Calculation
The Court determined that a royalty rate of 20% of the antenna price was a fair measure of damages. The total was calculated based on sales figures disclosed in the Defendants' affidavits:
- Royalty on INR-denominated sales: ₹36,94,69,435.84.
- Royalty on USD-denominated sales: $12,189,198.32.
- This amount was converted to Indian Rupees using the exchange rate as of the date of the decree (March 30, 2026), which was ₹94.6510 per USD.
- The converted USD-denominated royalty equals ₹115,37,67,348.06.
Payment Terms
- Deadline: The amount must be remitted within three months of the decree (by June 30, 2026).
- Interest: If not paid by the deadline, a simple interest of 7% per annum will be applied starting from July 1, 2026.
- Additional Sales: For sales made by the Defendants that were not yet accounted for in previous affidavits, the Defendants must file updated sales figures within four weeks. Damages for these additional sales will also be calculated at a 20% royalty rate
Decision here
